🔎 Trials Near Me

Dachaigh › Obesity › Ohio

Sgrùdaidhean clionaigeach Obesity ann an Ohio

Tha 46 sgrùdaidhean airson Obesity a’ lorg phàirtichean aig làraichean ann an Ohio.

Bailtean ann an Ohio

Teacsa sgrùdaidh oifigeil (Beurla)

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

  • Clinical Trial Investigator Clinical Research Center, Cincinnati
  • Velocity Clinical Research - Cincinnati, Cincinnati
A’ fastadhÌre 3
Aoisean 18 gu 99 · Gach gnè · Air ùrachadh 5 Dàmh 2026 · NCT07684235

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

  • Velocity Clinical Research - Cincinnati, Cincinnati
  • Velocity Clinical Research - Springdale, Cincinnati
A’ fastadhÌre 3
Aoisean 18 gu 99 · Gach gnè · Air ùrachadh 5 Dàmh 2026 · NCT07684144

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  • Velocity Clinical Research - Cleveland, Beachwood
  • Aultman Hospital, Cardiovascular Consultants, Inc, Canton
  • Velocity Clinical Research - Auburn, Cincinnati
  • agus 2 a bharrachd
A’ fastadhÌre 3
Aoisean 45 gu 99 · Gach gnè · Air ùrachadh 5 Dàmh 2026 · NCT07037433

Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

  • CTI Clinical Research Center /ID# 282043, Cincinnati
A’ fastadhÌre 2
Aoisean 18 gu 75 · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT07752979

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

  • Centricity Research - Ohio, Columbus
  • PriMed Clinical Research, Dayton
A’ fastadhÌre 3
Aoisean 8 gu 18 · Gach gnè · Air ùrachadh 30 Sult 2026 · NCT07253285

A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event

  • Velocity Clinical Research, Cincinnati, Springdale, Cincinnati
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 30 Sult 2026 · NCT07783802

A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

  • Midwest Eye Center, Cincinnati
  • Velocity Clinical Research, Mt. Auburn, Cincinnati
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 28 Sult 2026 · NCT07595549

Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D

  • Ohio Clinical Trials, Columbus
A’ fastadhÌre 1
Aoisean 18 gu 65 · Gach gnè · Air ùrachadh 28 Sult 2026 · NCT07399678

Comparing Reduction With ESD- Versus APC-TORe

  • Cleveland Clinic Foundation, Cleveland
A’ fastadhFàilte do shaor-thoilich fhallain
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 28 Sult 2026 · NCT06131281

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

  • Gastro Intestinal Research Institute of Northern Ohio, LLC, Westlake
A’ fastadhÌre 3
Aoisean 18 gu 70 · Gach gnè · Air ùrachadh 24 Sult 2026 · NCT06937099

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

  • Cleveland Clinic, Cleveland
  • Nationwide Children's Hospital, Columbus
A’ fastadhÌre 3
Aoisean 6 gu 17 · Gach gnè · Air ùrachadh 24 Sult 2026 · NCT06672549

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

  • Gastro Intestinal Research Institute of Northern Ohio, LLC, Westlake
A’ fastadhÌre 3
Aoisean 18 gu 70 · Gach gnè · Air ùrachadh 24 Sult 2026 · NCT06937086

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

  • CTI Clinical Research Center, Cincinnati
  • Care Access - Lima, Lima
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 22 Sult 2026 · NCT07392190

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

  • Care Access - Lima, Lima
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 22 Sult 2026 · NCT07282600

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

  • CTI Clinical Research Center, Cincinnati
A’ fastadhÌre 2
Aoisean 18 gu 75 · Gach gnè · Air ùrachadh 22 Sult 2026 · NCT07589608

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

  • CTI Clinical Research Center, Cincinnati
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 22 Sult 2026 · NCT07369011

A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

  • Research Site, Kent
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 22 Sult 2026 · NCT07784270

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

  • AURORA-2 Clinical Site, Cincinnati
  • AURORA-2 Clinical Site, Cleveland
  • AURORA-2 Clinical Site, Columbus
  • agus 1 a bharrachd
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 16 Sult 2026 · NCT07743450

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

  • AURORA-1 Clinical Site, Cincinnati
  • AURORA-1 Clinical Site, Cleveland
  • AURORA-1 Clinical Site, Columbus
  • agus 1 a bharrachd
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 16 Sult 2026 · NCT07743463

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

  • Remington Davis Inc, Columbus
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 14 Sult 2026 · NCT07351058

A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

  • Providence Health Partners-Center for Clinical Research, Dayton
A’ fastadhÌre 2
Aoisean 18 gu 75 · Gach gnè · Air ùrachadh 14 Sult 2026 · NCT06897475

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

  • Hometown Urgent Care and Research - Dayton, Dayton
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 14 Sult 2026 · NCT07351045

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

  • ACCOMPLISH-2 Research Site, Columbus
A’ fastadhÌre 3Fàilte do shaor-thoilich fhallain
Aoisean 18 gu 79 · Gach gnè · Air ùrachadh 11 Sult 2026 · NCT07654374

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

  • PriMED Clinical Research, Dayton
A’ fastadhÌre 2
Aoisean 18 gu 75 · Gach gnè · Air ùrachadh 8 Sult 2026 · NCT07215559

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

  • CTI Clinical Research Center, Cincinnati
A’ fastadhÌre 2
Aoisean 18 gu 75 · Gach gnè · Air ùrachadh 8 Sult 2026 · NCT06143956

Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

  • Kailera Clinical Site, Cleveland
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 3 Sult 2026 · NCT07284901

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

  • Research Site, Columbus
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Lùna 2026 · NCT07784725

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

  • Cincinnati Children's Hospital Medical Center, Cincinnati
A’ fastadhÌre 2
Aoisean 7 gu 25 · Gach gnè · Air ùrachadh 19 Lùna 2026 · NCT05082519

A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

  • Aultman Hospital, Canton
  • Lindner Center,Christ Hospital, Cincinnati
  • Louis Stokes Clvlnd VA Med Ctr, Cleveland
  • agus 4 a bharrachd
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 18 Lùna 2026 · NCT07567001

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

  • ACCOMPLISH-1 Research Site, Columbus
  • ACCOMPLISH-1 Research Site, Columbus
A’ fastadhÌre 3
Aoisean 18 gu 79 · Gach gnè · Air ùrachadh 10 Lùna 2026 · NCT07654361

Atomoxetine in Melanocortin Obesity Syndrome

  • Nationwide Children's Hospital, Columbus
A’ fastadhÌre 2
Aoisean 6 agus nas sine · Gach gnè · Air ùrachadh 7 Lùna 2026 · NCT06899178

Fibrosis Lessens After Metabolic Surgery

  • Cleveland Clinic, Cleveland
A’ fastadhÌre 4Fàilte do shaor-thoilich fhallain
Aoisean 18 gu 75 · Gach gnè · Air ùrachadh 31 Iuch 2026 · NCT06374875

Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists

  • The Ohio State University, Columbus
A’ fastadhSgrùdadh amharc
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 24 Iuch 2026 · NCT07702461

A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia

  • Ohio Clinical Trials, Columbus
A’ fastadhÌre 2
Aoisean 18 gu 80 · Gach gnè · Air ùrachadh 22 Iuch 2026 · NCT07477704

A Single and Multiple Ascending Dose Study of HM17321 in Healthy and Obese Participants

  • Medpace Clinical Pharmacology Unit, Cincinnati
A’ fastadhÌre 1Fàilte do shaor-thoilich fhallain
Aoisean 18 gu 65 · Gach gnè · Air ùrachadh 4 Cèit 2026 · NCT07219589

Dietary Peanuts and Nutrition-Related Outcomes

  • University Hospitals Cleveland Medical Center, Clevland
A’ fastadhFàilte do shaor-thoilich fhallain
Aoisean 18 gu 80 · Gach gnè · Air ùrachadh 23 Gibl 2026 · NCT07244458

Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.